The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer
about
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centreA randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.Management of operable primary breast cancer in older women.Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.Oestrogen receptor negative early operable primary breast cancer in older women-Biological characteristics and long-term clinical outcome.Trends in endpoint selection in clinical trials of advanced breast cancer.Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma.Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.FulvestrantSelection of Primary Breast Cancer Patients for Adjuvant Endocrine Therapy – is Oestrogen Receptor Alone Adequate?Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer
P2860
Q33197385-42E4307D-AB55-4157-A64E-12D89FAA3871Q35006855-DF21C094-1F99-4ADC-91A6-CCBC5D0C4F14Q36653598-8993C291-82DA-4196-AB1D-06D680FE5D89Q38254650-7D2B8BAC-E47E-4092-8D9D-4AAC0062144CQ39779772-3E31E5F0-9473-4EFB-AFAC-1782CC82E8CDQ43824354-8E0B7A30-6614-46B4-A772-C24DC0003AA8Q48336503-20F8BA8A-0C04-4E6A-8C14-CACA2A40B619Q50160426-DC666557-4C7C-471C-8870-E4C3D4D6F83DQ52962361-9AE0D0E6-D892-47E7-8614-C45F22812A29Q54065301-BF9B0ECA-F992-4237-B6C9-22F26D833058Q58834585-41BDFAEF-1746-4F54-A8EB-7C347E0A6465Q58834590-D4DB4B0D-8797-4D2F-A0E2-D28C42E24C24Q59289132-572F6911-3152-4654-B5A6-DB67DE62A9C5
P2860
The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer
description
im Oktober 1997 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 October 1997
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 1997
@uk
name
The clinical relevance of stat ...... in patients with breast cancer
@en
The clinical relevance of static disease
@nl
type
label
The clinical relevance of stat ...... in patients with breast cancer
@en
The clinical relevance of static disease
@nl
prefLabel
The clinical relevance of stat ...... in patients with breast cancer
@en
The clinical relevance of static disease
@nl
P2093
P1476
The clinical relevance of stat ...... in patients with breast cancer
@en
P2093
J F Robertson
P C Willsher
R W Blamey
P304
P356
10.1016/S0959-8049(97)00178-0
P577
1997-10-01T00:00:00Z